missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ CD264 (TRAIL-R4) Polyclonal Antibody

Rabbit Polyclonal Antibody
Brand: Invitrogen™ PA5102035
This item is not returnable.
View return policy
Description
Antibody detects endogenous levels of total TNFRSF10D.
TRAIL (also known as Apo-2L) is a member of the tumor necrosis factor (TNF) ligand family that rapidly induces apoptosis in a variety of transformed cell lines. A fourth member of the emerging TRAIL receptor family, TRAIL-R4, has signaling capacity similar to that of TRAIL-R1 and TRAIL-R2 with respect to NF-kappaB activation, but differs in its inability to induce apoptosis. Like TRAIL-R1 and TRAIL-R2, this receptor shows widespread tissue expression. The human TRAIL-R4 gene has been mapped to chromosome 8p22-21, clustered with three other TRAIL receptors.
Specifications
| CD264 (TRAIL-R4) | |
| Polyclonal | |
| Unconjugated | |
| TNFRSF10D | |
| CD264; DCR2; Decoy receptor 2; TNF receptor superfamily member 10d; TNF receptor-related receptor for TRAIL; TNF-related apoptosis-inducing ligand receptor 4; TNFRSF10D; TRAIL receptor 4; TRAIL receptor with a truncated death domain; TRAILR4; TRAIL-R4; TRUNDD; Tumor necrosis factor receptor superfamily member 10D; tumor necrosis factor receptor superfamily member 10d, decoy with truncated death domain; tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain; UNQ251/PRO288 | |
| Rabbit | |
| Affinity chromatography | |
| RUO | |
| 8793 | |
| -20°C | |
| Liquid |
| Western Blot, Immunocytochemistry | |
| 1 mg/mL | |
| PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
| Q9UBN6 | |
| TNFRSF10D | |
| A synthesized peptide derived from human TNFRSF10D(Accession Q9UBN6), corresponding to amino acid residues K122-C172. | |
| 100 μL | |
| Primary | |
| Human | |
| Antibody | |
| IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction